Gilead Sciences has announced royalty-free licensing agreements with six generic drug manufacturers to produce and sell lower-cost versions of its HIV prevention medicine, lenacapavir, in 120 low and lower-middle-income countries. This move aims to increase access to affordable HIV prevention and treatment options in regions most affected by the epidemic. The US-based pharmaceutical giant has partnered with India’s Dr Reddy’s…